WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) today announced that it has entered into a multi-year research support and collaboration agreement with Vanderbilt-Ingram Cancer Center (VICC) at Vanderbilt University Medical Center (VUMC), whereby Incyte will provide funding for certain aspects of Vanderbilt’s cancer research activities. This alliance is designed to develop an improved understanding of basic cancer biology and the mechanisms of action of certain Incyte-proprietary compounds, as well as identify and develop novel approaches to patient selection which may enable new therapeutic opportunities in oncology.
“The Incyte pipeline of targeted therapies represents an opportunity for researchers here at Vanderbilt to test important hypotheses in a scientifically-aligned mission. We envision a collaboration centered on advancing our mechanistic understanding of cancer therapies,” said Michael R. Savona, M.D., Director, Hematology Early Therapy Program, VICC/VUMC.
“Incyte and the Vanderbilt University Medical Center share a common goal of advancing innovative science to improve patients’ lives, and this alliance reflects this shared vision and the importance of collaborative research to achieve this end,” stated Reid Huber, Ph.D., Incyte’s Chief Scientific Officer. “We are pleased to be able to establish a support structure that expands novel cancer research capabilities at Vanderbilt, and aligns with Incyte’s strengths in oncology R&D.”
“We are excited by the opportunity to collaboratively investigate new molecular targets in cancer,” said Lawrence J. Marnett, Ph.D., Associate Vice-Chancellor for Research and Senior Associate Dean for Biomedical Sciences, VUMC. “Incyte scientists’ skills and interests nicely complement those of multiple investigators at Vanderbilt who study this disease.”
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. For additional information on Incyte, please visit the Company’s website at www.incyte.com.
Except for the historical information set forth herein, the matters set forth in this press release contain predictions, estimates and other forward-looking statements, including without limitation statements regarding the duration of the collaboration with Vanderbilt and whether the collaboration with Vanderbilt will achieve its intended goals.
These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to the efficacy or safety of Jakafi and the compounds in Incyte’s pipeline, the results of further research and development, the risks that results of clinical trials may be unsuccessful or insufficient to meet applicable regulatory standards, other market or economic factors, competitive and technological advances, and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended March 31, 2015. The Company disclaims any intent or obligation to update these forward-looking statements.